Lilly To Discontinue Select Humulin Offerings (Correction)
This article was originally published in The Pink Sheet Daily
Executive Summary
Lilly will discontinue only the Ultralente and Lente formulations of Humulin human insulin. The firm will continue to manufacture Humulin R, N, 70/30 and 50/50 formulations. "The Pink Sheet" DAILY had inadvertently suggested that all Humulin formulations were to be discontinued by year-end (1"The Pink Sheet" DAILY, July 6, 2005)
You may also be interested in...
Lilly To Discontinue Two Humulins - Ultralente and Lente - By Year-End
Company says declining commercial demand is the reason for its decision to discontinue production of the longer-acting Humulins as well as Iletin insulins. Lilly sends out "Dear Doctor" letters and will help transition patients to the company's other insulin products through coupons for free samples.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.